Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease

Koichi Kaikita ¹  Kazuya Hosokawa ²  Jeffrey R. Dahlen ³  Kenichi Tsujita ¹

¹ Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
² Research Institute, Fujimori Kogyo Co., Yokohama, Kanagawa, Japan
³ Hikari Dx, San Diego, California, United States

Address for correspondence Koichi Kaikita, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan (e-mail: kaikitak@kumamoto-u.ac.jp).

Introduction

Arterial and venous thrombosis play an important role in the pathogenesis of various cardiovascular diseases, and several pharmacological agents are clinically used to inhibit the cascade of thrombus formation. Antiplatelet agents represent the mainstay preventive strategy against systemic arterial thrombosis, as platelets play crucial roles in initiating thrombus formation.¹⁻³ Dual antiplatelet therapy (DAPT) with aspirin and P2Y₁₂ receptor inhibitors is established in patients with acute coronary syndrome or after percutaneous coronary intervention.

Various antithrombotic agents are clinically used to inhibit the cascade of arterial or venous thrombosis in cardiovascular diseases. Dual antiplatelet therapy with aspirin and P2Y₁₂ inhibitors is prescribed in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Direct oral anticoagulants (DOACs) are widely used for the prevention or treatment of thromboembolism in patients with atrial fibrillation (AF) and venous thromboembolism. However, there has been no definitive tool to simultaneously monitor the antithrombotic effects of these drugs. The Total Thrombus-Formation Analysis System (T-TAS), a microchip-based flow chamber system that mimics in vivo conditions for evaluating whole blood thrombogenicity, was developed for the quantitative analysis of thrombus formation in whole blood specimens. The utility of T-TAS has been evaluated in CAD patients treated with antiplatelet therapies. The T-TAS PL chip area under the flow pressure curve (AUC) accurately assesses primary hemostasis and is sensitive to the therapeutic effects of various antiplatelet therapies. In addition, low AUC results are a significant predictor of periprocedural bleeding events in CAD patients undergoing PCI. The T-TAS AR chip AUC result is useful for assessing the efficacy of DOACs and warfarin in AF patients undergoing catheter ablation, and it is also a potential independent predictor of periprocedural bleeding events and avoidance of thrombosis in patients having undergone total knee arthroplasty. In conclusion, T-TAS is a useful index for evaluating the total antithrombotic effects of combination antithrombotic agents in patients with various cardiovascular diseases.

Keywords

► T-TAS
► antiplatelet therapy
► direct oral anticoagulants
► antithrombotic therapy
► diagnostic test

Abstract

Various antithrombotic agents are clinically used to inhibit the cascade of arterial or venous thrombosis in cardiovascular diseases. Dual antiplatelet therapy with aspirin and P2Y₁₂ inhibitors is prescribed in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Direct oral anticoagulants (DOACs) are widely used for the prevention or treatment of thromboembolism in patients with atrial fibrillation (AF) and venous thromboembolism. However, there has been no definitive tool to simultaneously monitor the antithrombotic effects of these drugs. The Total Thrombus-Formation Analysis System (T-TAS), a microchip-based flow chamber system that mimics in vivo conditions for evaluating whole blood thrombogenicity, was developed for the quantitative analysis of thrombus formation in whole blood specimens. The utility of T-TAS has been evaluated in CAD patients treated with antiplatelet therapies. The T-TAS PL chip area under the flow pressure curve (AUC) accurately assesses primary hemostasis and is sensitive to the therapeutic effects of various antiplatelet therapies. In addition, low AUC results are a significant predictor of periprocedural bleeding events in CAD patients undergoing PCI. The T-TAS AR chip AUC result is useful for assessing the efficacy of DOACs and warfarin in AF patients undergoing catheter ablation, and it is also a potential independent predictor of periprocedural bleeding events and avoidance of thrombosis in patients having undergone total knee arthroplasty. In conclusion, T-TAS is a useful index for evaluating the total antithrombotic effects of combination antithrombotic agents in patients with various cardiovascular diseases.
percutaneous coronary intervention (PCI). In contrast, anticoagulant drugs are widely used for prophylaxis and treatment of venous thrombosis. Direct oral anticoagulants (DOACs) are widely useful for the prevention or treatment of thromboembolism in patients with atrial fibrillation (AF) and venous thromboembolism (VTE). Several diagnostic devices have recently been developed to evaluate the pathogenesis and therapies related to thrombotic and hemorrhagic disorders. 

Recently, the Total Thrombus-Formation Analysis System (T-TAS), a microchip-based flow chamber system designed to evaluate thrombogenicity in whole blood, was developed as an easy-to-use system for quantitative analysis of thrombus formation. T-TAS can assess the influence of antithrombotic agents on platelet activation and coagulation reactions over a collagen or collagen/tissue thromboplastin-coated surface. The pathogenesis and therapies related to thrombotic and hemorrhagic disorders.

**Measurement of Thrombogenicity by T-TAS**

As shown in the Virchow Triad, thrombosis is caused by a defect in blood flow, blood vessels, and/or blood components. T-TAS is an automated microchip-based flow chamber system designed for easy and quick assessment of platelet thrombus formation under physiological flow conditions, to approximate thrombus formation in vivo. This system analyzes different thrombus formation processes using a simple procedure comprising two microchips with different thrombogenic surfaces: a platelet (PL) chip specific for measuring primary hemostatic ability and an atheroma (AR) chip for measuring fibrin-rich platelet thrombus formation. The PL chip is coated with type I collagen, and platelets adhere via von Willebrand factor (vWF) to the surface of the collagen and aggregate inside the microchip, leading to occlusion of the microchip capillaries. The AR chip is coated with type I collagen plus tissue thromboplastin, which simultaneously activates platelets and the coagulation system, respectively, inside the microchip. The process of thrombus formation inside the chips can be analyzed by monitoring the change in flow pressure. The area under the flow pressure curve (AUC) was computed to assess the thrombogenicity inside the microchips. The AUC over 10 minutes is computed for the PL chip and the AUC over 30 minutes is computed for the AR chip. A version of the T-TAS instrument called T-TAS Plus was developed for the research setting and has user-selectable flow rates and video capture capability. PL chip flow rates of 18 and 24 μL/min are defined as PL18-AUC10 and PL24-AUC10, which correspond to shear stresses of 1,500 s⁻¹ and 2,000 s⁻¹, respectively. A previous study showed the significant positive correlation between PL18-AUC10 and PL24-AUC10 (or simply, PL-AUC) levels in samples from the patients with cardiovascular disease. The AR chip is typically tested at a flow rate of 10 μL/min, defined as AR10-AUC30 (or simply, AR-AUC), which corresponds to a shear rate of 600 s⁻¹. An in vitro diagnostic version of T-TAS has been developed that uses fixed flow rates of 18 and 10 μL/min for the PL and AR chips, respectively, and does not contain video capture capabilities.

**Comparison of Methods for Various Platelet Function Assessments and T-TAS**

<table>
<thead>
<tr>
<th>Chip</th>
<th>Type of thrombi</th>
<th>Anticoagulants in blood tube</th>
<th>Capillary coating</th>
<th>Shear rates</th>
<th>Assay time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL chip</td>
<td>Platelet thrombi</td>
<td>Hirudin or BAPA</td>
<td>Type 1 collagen (pig tendon)</td>
<td>1,000, 1,500, or 2,000/s</td>
<td>≤10 min</td>
</tr>
<tr>
<td>AR chip</td>
<td>Fibrin rich platelet thrombi</td>
<td>Citrate</td>
<td>Type 1 collagen (pig tendon)</td>
<td>240 or 600/s</td>
<td>≤30 min</td>
</tr>
</tbody>
</table>

**Table 1 Technical characteristics of T-TAS assay chips**

Abbreviations: AR, atheroma; BAPA, benzylsulfonyl-D-Arg-Pro-4-amidinobenzylamide; PL, platelet; T-TAS, Total Thrombus-Formation Analysis System.
epinephrine or ADP to evaluate the effects of aspirin or P2Y12 receptor inhibitors under arterial shear conditions; however, the results of this assay are also agonist-dependent. Although these systems are less labor-intensive than light transmittance aggregometry and permit the use of whole blood, their results reflect platelet activity primarily based on the specific pathway activated by the soluble exogenous agonist, and they are insensitive to the contribution of other mechanisms for platelet activation. Therefore, while these tests are useful for assessing the activity or blockade of a particular platelet activation pathway, they are of limited utility for monitoring overall primary hemostasis. The PL assay reflects the three major steps in platelet thrombus formation: vWF-mediated platelet adhesion, the release of endogenous platelet agonists, and platelet activation and aggregation. While the PL assay is able to assess overall primary hemostasis, it is not able to specifically evaluate individual platelet activation pathways and cannot provide information about the reason for impaired primary hemostatic function. In this regard, the PL assay and agonist-based assays are complimentary and their combined use can provide a comprehensive analysis of primary hemostasis.

Further, while plasma-based prothrombin time (PT) and activated partial thromboplastin time (APTT) are commonly used to titrate warfarin and heparin for monitoring the efficacy of anticoagulant treatments, PT and APTT do not reflect the interaction between coagulation factors and platelets in vivo. Rotational thromboelastometry (ROTEM [Tem Innovations GmbH, Munich, Germany]) is frequently used to measure viscoelastic changes due to fibrin formation and platelet activation during thrombus formation in whole blood. ROTEM is potentially useful for evaluating the antithrombotic effects of low molecular weight heparin, direct thrombin, or Xa inhibitors, although it is relatively insensitive for platelet function and not suitable for evaluating efficacy of antiplatelet agents. Additionally, a major limitation of ROTEM is the lack of blood flow that affects the supply and washout of platelets, coagulation factors, and inhibitors.

Table 2 Comparison of whole blood methods for platelet function assessment

<table>
<thead>
<tr>
<th>Assay type</th>
<th>VerifyNow</th>
<th>Multiplate</th>
<th>PFA-100</th>
<th>T-TAS PL chip</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood flow</td>
<td>Pathway-specific assay</td>
<td>Pathway-specific assay</td>
<td>Pathway-dependent assay</td>
<td>Global assay</td>
</tr>
<tr>
<td>Platelet activators</td>
<td>Soluble exogenous agonist(s)</td>
<td>Soluble exogenous agonist(s)</td>
<td>Soluble exogenous agonist(s)</td>
<td>Collagen surface Shear stress</td>
</tr>
<tr>
<td>Analysis</td>
<td>Agglutination Aggregation</td>
<td>Nonspecific adhesion Aggregation</td>
<td>Adhesion Aggregation</td>
<td>Thrombus formation</td>
</tr>
<tr>
<td>Parameters</td>
<td>Pathway-specific reaction units</td>
<td>Area under the impedance-time curve</td>
<td>Closure time</td>
<td>Area under the flow pressure-time curve</td>
</tr>
</tbody>
</table>

Abbreviations: PL, platelet; T-TAS, Total Thrombus-Formation Analysis System.

Fig. 1 Primary differences between the Total Thrombus-Formation Analysis System (T-TAS) platelet (PL) assay and other available assays for measuring platelet activity within the scope of overall primary hemostasis.
Assessment of Total Thrombogenicity in Patients with Coronary Artery Disease and Cerebrovascular Disease Treated with Various Antiplatelet Agents

Antiplatelet therapy is used for the prevention of coronary artery disease (CAD) and cerebrovascular disease (CVD). Aspirin is used as the mainstay drug for secondary prevention of ischemic cardiovascular events and its concomitant use with platelet P2Y₁₂ receptor inhibitors can reduce the risk of thrombotic events after stent implantation. Clopidogrel is a commonly used thienopyridine drug, and requires biotransformation to an active metabolite by the enzyme cytochrome P450 2C19 (cytochrome P-450 2C19 [CYP2C19]). In contrast, prasugrel is a third-generation thienopyridine used for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing PCI. Compared with clopidogrel, prasugrel has a faster onset of action, greater inhibitory effect on platelet aggregation at clinical doses, and lower risk of thrombotic events after stent implantation. Prasugrel is associated with higher rates of bleeding, especially in patients with CYP2C19 genetic variant carriers. Ticagrelor is another potent antiplatelet agent that reversibly binds to the platelet P2Y₁₂ receptor.

The efficacy of antiplatelet therapy can be assessed by several techniques. The VerifyNow assay is an easy-to-use point-of-care system in which increased light transmission is used to reflect agonist-induced platelet aggregation with fibrinogen-coated latex beads. VerifyNow can be used to assess efficacy and safety of different antiplatelet drugs by using different cartridges specific for P2Y₁₂, aspirin, or glycoprotein IIb/IIIa inhibitor. Using this system, the platelet response to aspirin and P2Y₁₂ receptor inhibitors is expressed as aspirin reaction units (ARUs) and P2Y₁₂ reaction units (PRUs), respectively, with the PRU level being influenced by CYP2C19 genotype and correlated with cardiovascular events.

There have been several reports in the analyses of antiplatelet therapies comparing the PL chip and agonist-dependent platelet function tests. As shown in Table 3, in a report of Arima et al., samples from patients with cardiovascular disease taking no antiplatelet medication (controls), treated with aspirin, and treated with DAPT were comparatively analyzed with VerifyNow PRU and PL chip. The PRU levels were lower in the aspirin/clopidogrel group than the control and aspirin groups, but there were no significant differences in PRU levels between the control and aspirin groups. On the other hand, the PL-AUC levels were significantly lower in the two antiplatelet therapy groups compared with the control group, and the level was significantly lower in the aspirin/clopidogrel group than the aspirin group, which were mostly

<table>
<thead>
<tr>
<th>Study</th>
<th>Population (n)</th>
<th>Tests</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hosokawa et al, 2013</td>
<td>72 ACS patients and healthy control</td>
<td>T-TAS PL chip Multiplate</td>
<td>PL chip AUC was decreased in aspirin-only patients, and was further decreased in DAPT patients. Multiplate AUC showed the same values for aspirin and DAPT groups with arachidonic acid, and showed the same values for controls and aspirin groups with ADP.</td>
</tr>
<tr>
<td>Arima et al., 2016</td>
<td>274 patients suspected CAD</td>
<td>T-TAS PL chip VerifyNow</td>
<td>PL chip AUC was decreased with aspirin alone, and decreased even further by DAPT. VerifyNow PRU was lower in the DAPT group compared with the control group but not with the aspirin group</td>
</tr>
<tr>
<td>Yamazaki et al, 2016</td>
<td>94 patients with ischemic stroke</td>
<td>T-TAS PL chip VerifyNow</td>
<td>PL chip AUC was lower in patients with DAPT compared with aspirin or clopidogrel alone. Clopidogrel low responders analyzed by PL chip AUC predicted carotid or intracranial arterial stenosis. VerifyNow PRU in patients with DAPT and clopidogrel alone showed similar values and were lower compared than aspirin alone. VerifyNow ARU in patients with DAPT and aspirin alone showed similar values and were lower than clopidogrel alone.</td>
</tr>
<tr>
<td>Oimatsu et al, 2017</td>
<td>313 CAD patients with PCI</td>
<td>T-TAS PL chip VerifyNow</td>
<td>AR chip AUC but not VerifyNow PRU was lower in patients that experienced periprocedural bleeding during PCI.</td>
</tr>
<tr>
<td>Borst et al, 2018</td>
<td>40 NSTEMI patients with PCI</td>
<td>T-TAS AR chip TG</td>
<td>AR chip AUC and TG reflected the effect of triple antithrombotic therapy with DAPT and very low-dose rivaroxaban post-PCI.</td>
</tr>
<tr>
<td>Ito et al, 2016</td>
<td>128 AF patients with CA</td>
<td>T-TAS AR chip PT/APTT</td>
<td>AR chip AUC but not PT and APTT was lower in AF patients with periprocedural bleeding after CA.</td>
</tr>
<tr>
<td>Sueta et al, 2018</td>
<td>38 patients with TKA</td>
<td>T-TAS AR chip PT/APTT</td>
<td>AR chip AUC and PT/APTT were lower in the combination therapy group 7 d after than before TKA.</td>
</tr>
</tbody>
</table>

Abbreviations: ACS, acute coronary syndrome; ADP, adenosine diphosphate; AF, atrial fibrillation; APTT, activated partial thromboplastin time; AR, atheroma; ARU, aspirin reaction unit; AUC, area under the curve; CA, catheter ablation; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PL, platelet; PRU, P2Y₁₂ reaction unit; PT, prothrombin time; T-TAS, Total Thrombus-Formation Analysis System; TG, thrombin generation; TKA, total knee arthroplasty.
consistent with data from other clinical studies.\textsuperscript{55,56} In the DAPT group, the PL-AUC level was higher in poor metabolizers (PMs) with CYP2C19 polymorphism than in non-PMs. These findings suggest that the T-TAS PL-AUC level might be useful to assess the combined, overall therapeutic effects of multiple antiplatelet therapies, particularly since the values decreased as the potency of antiplatelet therapy increased.

Periprocedural bleeding events are one of the most common complications after PCI, and patients with periprocedural bleeding have an increased risk of readmission for treatment of recurrent bleeding, major adverse cardiovascular events, and all-cause mortality compared to those without periprocedural bleeding.\textsuperscript{57–61} While the development of various bleeding avoidance strategies, such as the radial approach, vascular closure devices, and bivalirudin, has reduced the incidence of periprocedural bleeding after PCI, the rate has remained relatively high in several studies.\textsuperscript{62–64} The incidence rate of major PCI-related periprocedural bleeding in Japanese patients with acute coronary syndrome is 4.8% for the femoral approach and 1.1% for the radial approach, and that of elective PCI for CAD is 2.2% for the femoral approach and 0.2% for the radial approach.\textsuperscript{65} However, it was unclear from previous studies how the combined antithrombotic effects by different types of drugs were associated with periprocedural bleeding events in CAD patients undergoing PCI. Oimatsu et al reported that PL-AUC levels were significantly lower in patients with than in those without such events, and that there was a significant association between low PL-AUC levels and periprocedural bleeding events as defined by the International Society on Thrombosis and Haemostasis.\textsuperscript{66}

Yamazaki et al performed analysis of CVD patient samples on aspirin alone, clopidogrel alone, and DAPT with PL chip and VerifyNow system. The AUC for PL chip was lower for those in the DAPT group than those in the aspirin or clopidogrel alone group. In contrast, VerifyNow ARU in the aspirin and DAPT groups was the same, and VerifyNow PRU showed the same values in clopidogrel and DAPT patients, indicating that the results overall were very characteristic of an agonist (cartridge)-dependent assay.\textsuperscript{56} In this way, analysis of platelet thrombus formation with PL chip can comparatively evaluate the single and combined efficacies of aspirin and clopidogrel on platelet thrombus formation while VerifyNow system can only be used to analyze the separate effects of aspirin and clopidogrel.

In T-TAS PL chip analysis, poor responders to aspirin monotherapy had increased multiple platelet aggregates as analyzed by fluorescence-activated cell sorting.\textsuperscript{55} In addition, poor responders to clopidogrel monotherapy had increased rates of carotid or intracranial arterial stenosis.\textsuperscript{56} PL chip AUC was a good predictor of patients with PM CYP2C19 reduced function genotypes in DAPT patients, and combined use of PRU further enhanced the discrimination.\textsuperscript{42} By using both a global assay such as the PL chip and one of the conventional agonist-dependent assays together, the information about both the inhibition of receptors and enzymes by individual drugs, and the effect on overall platelet thrombus formation, can be obtained, which could be useful from the viewpoint of selecting and tailoring appropriate antiplatelet therapy for individual patients.

Borst et al showed that fibrin-rich platelet thrombus formation in AR chip was significantly inhibited by triple antiplatelet therapy with aspirin, clopidogrel, and very low-dose rivaroxaban in patients with non-ST-elevation myocardial infarction post-PCI.\textsuperscript{67} Conventionally, the antiplatelet function of aspirin and clopidogrel (reactivity to agonist) and the anticoagulant ability of rivaroxaban have been measured separately. However, all of these drugs are used for the same purpose: to inhibit thrombosis. Many clinical trials have confirmed that combined use of these drugs will decrease vascular events, but will increase bleeding risk. Quantitatively evaluating the comprehensive antithrombotic potential of these drugs may be useful for determining an antithrombotic therapy that is appropriate for individual patients.

**Assessment of Total Thrombogenicity and Periprocedural Bleeding Events in Patients undergoing Catheter Ablation for AF Treated with Anticoagulants**

Anticoagulants are useful agents for preventing cerebrovascular events in patients with AF. A previous study reported that warfarin reduced the risk of stroke by 64% compared with placebo.\textsuperscript{68} DOACs have been clinically used in recent years for the prevention of cerebrovascular events in patients with nonvalvular AF. Importantly, accumulating clinical and experimental evidence indicates that DOACs, such as dabigatran,\textsuperscript{16} apixaban,\textsuperscript{17} rivaroxaban,\textsuperscript{18} and edoxaban,\textsuperscript{19} in addition to warfarin, can reduce the likelihood of cerebrovascular events in nonvalvular AF patients. A recent network meta-analysis demonstrated that DOACs appear to be at least equivalent to warfarin at preventing stroke in AF patients and to carry a reduced risk of bleeding.\textsuperscript{69}

DOACs are innovative drugs that have resolved complex patient management issues associated with the administration of warfarin alone, such as frequent blood sampling, diet restriction, and drug interactions. However, there is no definitive tool for monitoring the anticoagulant effects of DOACs, even though some patients suffer bleeding complications due to excessively high blood concentrations of DOACs.\textsuperscript{70,71} Routine coagulation test parameters, such as the PT-international normalized ratio or APTT may be problematic for monitoring the anticoagulant effects of DOACs because individual DOACs have different characteristic chemical structures and different pharmacokinetic profiles (e.g., plasma half-life and tissue penetration rate).\textsuperscript{72} In the study of Ito et al, blood samples of AF patients undergoing catheter ablation (CA) were evaluated with AR chip.\textsuperscript{73} Blood samples obtained on the day of CA (anticoagulant-free point), and 3 days and 1 month after CA were evaluated using T-TAS to measure AR-AUC levels in two groups: those treated with warfarin and those treated with DOACs. The findings were: (1) AR-AUC levels were similar in the two groups on the day of CA; (2) AR-AUC levels were significantly lower in the two groups at 3 days and 1 month after CA than on the day of CA; and (3) AR-AUC level on the day of CA and 3 days after CA was a significant predictor of periprocedural bleeding events by receiver-operating characteristic
analysis. In this study, few AF patients developed thrombotic events after CA, possibly because of the continuous anticoagulant therapies after CA. While T-TAS is almost certainly expected to have clinical value, large-scale clinical studies are needed to confirm the usefulness of this device for monitoring thrombotic and bleeding events after CA.

Prophylaxis of VTE by Edoxaban after Total Knee Arthroplasty

In orthopedic surgery, VTE often occurs during the perioperative period of total hip arthroplasty, total knee arthroplasty (TKA), and hip fracture surgery. Many cases are fatal once pulmonary thromboembolism occurs. Western and Japanese guidelines for the diagnosis, treatment, and prevention of VTE recommend physiotherapy or anticoagulation therapy for preventing VTE in high-risk patients, including after TKA. In a recent clinical study, 38 patients were randomly assigned to the physiotherapy group (N = 19) or the physiotherapy plus 30 mg/day of edoxaban group (N = 19). As a result, the combination therapy significantly reduced the incidence of VTE after TKA compared to monotherapy, with the significant decrease of AR-AUC levels in the combination therapy group 7 days after TKA than before TKA.

Limitations

T-TAS is suitable to measure platelet function or coagulation as a global assay but not able to specially evaluate the activity of a pathway that may be targeted by an antithrombotic agent. For example, using T-TAS, it is possible to identify that overall primary hemostatic function has been impaired, but it is difficult to determine which drug is responsible for low PL-AUC levels in patients treated with DAPT, aspirin, or a P2Y12 receptor blocker. The soluble agonist-based VerifyNow and Multiplate systems are specific for certain platelet activation pathways but are not suitable to monitor global platelet function or overall primary hemostatic function in patients treated with DAPT. The combined use of the T-TAS and VerifyNow (or Multiplate) systems might be beneficial to determine both the specific antiplatelet drug effects on their targeted platelet activation pathways, and also their combined effect on overall primary hemostatic function in patients treated with DAPT.

An additional limitation is that a PL-AUC or AR-AUC threshold associated with thrombotic risk has not yet been conclusively identified. The recent published clinical studies were performed at a single center on a relatively small number of patients and may therefore be underpowered for the accurate detection of differences in thrombotic event rates. Therefore,
additional studies in larger populations are needed to further examine the relationship between PL-AUC or AR-AUC level measured by T-TAS and an increased risk of thrombotic cardiovascular events, as well as to further evaluate the association between T-TAS results and bleeding events.

Conclusion and Future Perspectives
As summarized in this review, recent clinical studies suggest that T-TAS is suitable for assessing the effects of different antiplatelet therapies such as aspirin and thienopyridines, and anticoagulant therapies such as warfarin and DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban). Further, PL chip and AR chip AUCs measured by the T-TAS might be useful for predicting peri-procedural bleeding events after various types of cardiovascular interventions.

As shown in – Fig. 2, various antithrombotic strategies such as antiplatelet therapies (aspirin and P2Y12 inhibitors) for CAD and anticoagulant therapies (DOACs, warfarin, and heparin) for AF or VTE are clinically used to inhibit the cascade of arterial or venous thrombosis in cardiovascular diseases. However, a combination of antiplatelet and anticoagulant therapies must be selected for patients with CAD complicated with AF and/or VTE. Several diagnostic devices for monitoring antiplatelet treatments, such as VerifyNow, Multiplate, and PFA-100, and devices and parameters for monitoring anticoagulant treatments, such as PT, APTT, and ROTEM, are limited when measuring whole blood thrombogenicity in patients receiving combination antiplatelet and anticoagulant therapies. T-TAS parameters (PL-AUC and AR-AUC) might be more effective for evaluating the total antithrombotic effects of combination antithrombotic agents in patients with various cardiovascular interventions.

Recent randomized clinical trials such as PIONEER AF-PCI78 or RE-DUAL PCI79 have demonstrated the efficacy and safety of combined antiplatelet therapy and a DOAC (rivaroxaban and dabigatran, respectively) in nonvalvular AF patients who have undergone PCI. In the PIONEER AF-PCI trial, administration of either low-dose rivaroxaban plus a P2Y12 receptor inhibitor for 12 months or very low-dose rivaroxaban plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding than standard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months. In the RE-DUAL PCI trial, the risk of bleeding was lower among CAD patients with AF who had undergone PCI and received dual therapy with dabigatran and a P2Y12 receptor inhibitor than among those who received triple therapy comprising warfarin, a P2Y12 receptor inhibitor, and aspirin. However, these studies lacked a monitoring system to evaluate the efficacy and safety of the combination of antiplatelet and anticoagulation therapies. T-TAS may be a useful system for evaluating the potential efficacy and safety of antithrombotic therapies in various cardiovascular diseases.

Conflict of Interest

Acknowledgments
The authors thank Yuichiro Arima, Daisuke Sueta, Miwa Ito, Masanobu Ishii, Yu Oimatsu, Tatsuro Mitsuse, Nobuhiro Nakashima, Satomi Iwashita, and Aya Takahashi of the Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, for their excellent support in the research. The authors also thank Tomoko Ohnishi of the Research Institute, Fujimori Kogyo Co., Yokohama, Kanagawa, Japan, for her excellent technical support and advice.

References
8 Gerschutz GP, Bhatt DL; Clopidogrel in Unstable Angina to Prevent Recurrent Events study. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? Am Heart J 2003;145(04):595–601

Funding
This study was supported in part by Grants-in-Aid for Scientific Research (#15K09089) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Conflict of Interest

Acknowledgments
The authors thank Yuichiro Arima, Daisuke Sueta, Miwa Ito, Masanobu Ishii, Yu Oimatsu, Tatsuro Mitsuse, Nobuhiro Nakashima, Satomi Iwashita, and Aya Takahashi of the Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, for their excellent support in the research. The authors also thank Tomoko Ohnishi of the Research Institute, Fujimori Kogyo Co., Yokohama, Kanagawa, Japan, for her excellent technical support and advice.

References
8 Gerschutz GP, Bhatt DL; Clopidogrel in Unstable Angina to Prevent Recurrent Events study. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? Am Heart J 2003;145(04):595–601

Funding
This study was supported in part by Grants-in-Aid for Scientific Research (#15K09089) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Role of T-TAS in Cardiovascular Disease  
Kaikita et al.


44 Frelinger AL III, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existing variability in platelet function. J Am Coll Cardiol 2013;61(08)::872–885

45 Angiolillo DJ. Variability in responsiveness to oral antithrombotic therapy. Am J Cardiol 2009;103(3, Suppl):S27–S34A


Vora AN, Rao SV. Bleeding complications after PCI and the role of transradial access. Curr Treat Options Cardiovasc Med 2014;16(05):305


